Diffusion Pharmaceuticals Inc. (DFFN): Price and Financial Metrics


Diffusion Pharmaceuticals Inc. (DFFN): $6.15

-0.08 (-1.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DFFN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DFFN Stock Price Chart Interactive Chart >

Price chart for DFFN

DFFN Price/Volume Stats

Current price $6.15 52-week high $19.80
Prev. close $6.23 52-week low $4.64
Day low $6.15 Volume 3,420
Day high $6.40 Avg. volume 9,928
50-day MA $5.96 Dividend yield N/A
200-day MA $6.43 Market Cap 12.54M

Diffusion Pharmaceuticals Inc. (DFFN) Company Bio


Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. The company is based in Charlottesville, Virginia.


DFFN Latest News Stream


Event/Time News Detail
Loading, please wait...

DFFN Latest Social Stream


Loading social stream, please wait...

View Full DFFN Social Stream

Latest DFFN News From Around the Web

Below are the latest news stories about DIFFUSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DFFN as an investment opportunity.

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting

GlobeNewswire | December 16, 2022

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing

Closing Dates of LifeSci-led Mergers Closing Dates of LifeSci-led Mergers Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies participating in review processLifeSci invited to participate in review process on same terms as all other bidders following submission of client’s unsolicited offer, but LifeSci instead chose to launch a proxy contest against our high

Yahoo | December 5, 2022

DFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23…

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating Strategic Opportunities On November 14, 2022, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) provided an update for its previously announced evaluation of strategic opportunities, which may include a sale, merger, divestiture, recapitalization, or other strategic transaction. Since announcing its

Yahoo | December 1, 2022

LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals

Sets the Record Straight on Diffusion’s Misleading Narrative and Raises Concerns about a Troubling Pattern of Entrenchment and Lack of Accountability on the Board Has Nominated a Slate of Highly Qualified Directors NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- LifeSci Special Opportunities Master Fund Ltd. (“LifeSci Special Opportunities” or “we”), the holder of 96,976 shares of common stock of Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”) (NASDAQ: DFFN), or approximately 4.8% of t

Yahoo | November 17, 2022

Diffusion Pharmaceuticals GAAP EPS of -$1.37 beats by $0.69

Diffusion Pharmaceuticals press release (DFFN): Q3 GAAP EPS of -$1.37 beats by $0.69.As of September 30, 2022, Diffusion had $25.9M in cash, cash equivalents, and marketable…

Seeking Alpha | November 15, 2022

Read More 'DFFN' Stories Here

DFFN Price Returns

1-mo 9.82%
3-mo 32.54%
6-mo -10.35%
1-year -56.55%
3-year -72.11%
5-year -98.67%
YTD 21.61%
2022 -66.84%
2021 -61.64%
2020 72.56%
2019 -76.85%
2018 -88.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7524 seconds.